214 related articles for article (PubMed ID: 30188117)
21. Mechanism of action of P-glycoprotein in relation to passive membrane permeation.
Eytan GD; Kuchel PW
Int Rev Cytol; 1999; 190():175-250. PubMed ID: 10331240
[TBL] [Abstract][Full Text] [Related]
22. Functionalized Multiwalled Carbon Nanotubes as Carriers of Ruthenium Complexes to Antagonize Cancer Multidrug Resistance and Radioresistance.
Wang N; Feng Y; Zeng L; Zhao Z; Chen T
ACS Appl Mater Interfaces; 2015 Jul; 7(27):14933-45. PubMed ID: 26107995
[TBL] [Abstract][Full Text] [Related]
23. MDR1/P-glycoprotein expression in colorectal cancer.
Linn SC; Giaccone G
Eur J Cancer; 1995; 31A(7-8):1291-4. PubMed ID: 7577038
[TBL] [Abstract][Full Text] [Related]
24. In vivo and in vitro multitracer analyses of P-glycoprotein expression-related multidrug resistance.
Márián T; Szabó G; Goda K; Nagy H; Szincsák N; Juhász I; Galuska L; Balkay L; Mikecz P; Trón L; Krasznai Z
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1147-54. PubMed ID: 12830325
[TBL] [Abstract][Full Text] [Related]
25. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
[TBL] [Abstract][Full Text] [Related]
26. Development of an intrinsic P-glycoprotein-mediated doxorubicin resistance in quiescent cell layers of large, multicellular prostate tumor spheroids.
Wartenberg M; Frey C; Diedershagen H; Ritgen J; Hescheler J; Sauer H
Int J Cancer; 1998 Mar; 75(6):855-63. PubMed ID: 9506530
[TBL] [Abstract][Full Text] [Related]
27. An Update on Circumventing Multidrug Resistance in Cancer by Targeting P-Glycoprotein.
Yang X; Li X; Duan Z; Wang X
Curr Cancer Drug Targets; 2018; 18(7):677-696. PubMed ID: 28820055
[TBL] [Abstract][Full Text] [Related]
28. The multidrug transporter P-glycoprotein: a mediator of melanoma invasion?
Colone M; Calcabrini A; Toccacieli L; Bozzuto G; Stringaro A; Gentile M; Cianfriglia M; Ciervo A; Caraglia M; Budillon A; Meo G; Arancia G; Molinari A
J Invest Dermatol; 2008 Apr; 128(4):957-71. PubMed ID: 17943188
[TBL] [Abstract][Full Text] [Related]
29. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells.
Stein U; Walther W; Shoemaker RH
J Natl Cancer Inst; 1996 Oct; 88(19):1383-92. PubMed ID: 8827016
[TBL] [Abstract][Full Text] [Related]
30. Effects of MDR1/P-glycoprotein expression on prognosis in advanced colorectal cancer after surgery.
Tokunaga Y; Hosogi H; Hoppou T; Nakagami M; Tokuka A; Ohsumi K
Oncol Rep; 2001; 8(4):815-9. PubMed ID: 11410790
[TBL] [Abstract][Full Text] [Related]
31. Decreased uptake of cyclosporin A by P-glycoprotein (Pgp) expressing CEM leukemic cells and restoration of normal retention by Pgp blockers.
Didier A; Wenger J; Loor F
Anticancer Drugs; 1995 Oct; 6(5):669-80. PubMed ID: 8845477
[TBL] [Abstract][Full Text] [Related]
32. Suppression of c-Myc is involved in multi-walled carbon nanotubes' down-regulation of ATP-binding cassette transporters in human colon adenocarcinoma cells.
Wang Z; Xu Y; Meng X; Watari F; Liu H; Chen X
Toxicol Appl Pharmacol; 2015 Jan; 282(1):42-51. PubMed ID: 25461681
[TBL] [Abstract][Full Text] [Related]
33. The cancer targeting potential of D-α-tocopheryl polyethylene glycol 1000 succinate tethered multi walled carbon nanotubes.
Mehra NK; Verma AK; Mishra PR; Jain NK
Biomaterials; 2014 May; 35(15):4573-88. PubMed ID: 24612818
[TBL] [Abstract][Full Text] [Related]
34. Redox regulation of P-glycoprotein-mediated multidrug resistance in multicellular prostate tumor spheroids.
Wartenberg M; Fischer K; Hescheler J; Sauer H
Int J Cancer; 2000 Jan; 85(2):267-74. PubMed ID: 10629088
[TBL] [Abstract][Full Text] [Related]
35. Diverse effects of P-glycoprotein inhibitory agents on human leukemia cells expressing the multidrug resistance protein (MRP).
Lehne G; Mørkrid L; den Boer M; Rugstad HE
Int J Clin Pharmacol Ther; 2000 Apr; 38(4):187-95. PubMed ID: 10783828
[TBL] [Abstract][Full Text] [Related]
36. N-desmethyl tamoxifen and quercetin-loaded multiwalled CNTs: A synergistic approach to overcome MDR in cancer cells.
Kumar M; Sharma G; Misra C; Kumar R; Singh B; Katare OP; Raza K
Mater Sci Eng C Mater Biol Appl; 2018 Aug; 89():274-282. PubMed ID: 29752099
[TBL] [Abstract][Full Text] [Related]
37. P-glycoprotein-mediated resistance to chemotherapy in cancer cells: using recombinant cytosolic domains to establish structure-function relationships.
Di Pietro A; Dayan G; Conseil G; Steinfels E; Krell T; Trompier D; Baubichon-Cortay H; Jault J
Braz J Med Biol Res; 1999 Aug; 32(8):925-39. PubMed ID: 10454753
[TBL] [Abstract][Full Text] [Related]
38. P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP) expression in acute promyelocytic leukaemia.
Michieli M; Damiani D; Ermacora A; Geromin A; Michelutti A; Masolini P; Baccarani M
Br J Haematol; 2000 Mar; 108(4):703-9. PubMed ID: 10792272
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and evaluation of Strychnos alkaloids as MDR reversal agents for cancer cell eradication.
Munagala S; Sirasani G; Kokkonda P; Phadke M; Krynetskaia N; Lu P; Sharom FJ; Chaudhury S; Abdulhameed MD; Tawa G; Wallqvist A; Martinez R; Childers W; Abou-Gharbia M; Krynetskiy E; Andrade RB
Bioorg Med Chem; 2014 Feb; 22(3):1148-55. PubMed ID: 24405813
[TBL] [Abstract][Full Text] [Related]
40. Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines.
Lehne G; De Angelis P; Clausen OP; Rugstad HE
Br J Cancer; 1996 Dec; 74(11):1719-29. PubMed ID: 8956784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
